S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
NASDAQ:IMAB

I-Mab (IMAB) Stock Price, News & Analysis

$1.87
0.00 (0.00%)
(As of 03:21 PM ET)
Today's Range
$1.84
$1.90
50-Day Range
$1.54
$2.01
52-Week Range
$1.16
$3.88
Volume
160,740 shs
Average Volume
529,093 shs
Market Capitalization
$150.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.25

I-Mab MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
551.6% Upside
$12.25 Price Target
Short Interest
Healthy
1.35% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.09mentions of I-Mab in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.97) to ($1.72) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.13 out of 5 stars

Medical Sector

431st out of 939 stocks

Pharmaceutical Preparations Industry

201st out of 433 stocks

IMAB stock logo

About I-Mab Stock (NASDAQ:IMAB)

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

IMAB Stock Price History

IMAB Stock News Headlines

I-Mab's (IMAB) "Buy" Rating Reaffirmed at HC Wainwright
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
I-Mab (NASDAQ:IMAB) PT Lowered to $6.00
Short Interest in I-Mab (NASDAQ:IMAB) Drops By 5.3%
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
I-MAB Stock (NASDAQ:IMAB), Short Interest Report
I-Mab to Divest Chinese Unit for Up to $80M
I-Mab (IMAB) interactive stock chart – Yahoo Finance
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
Ray Dalio on Potential US China War and Rise of China
Expert Ratings for I-MAB
See More Headlines
Receive IMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for I-Mab and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMAB
Fax
N/A
Employees
228
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.25
High Stock Price Target
$25.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+555.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.89 million
Book Value
$2.93 per share

Miscellaneous

Free Float
62,867,000
Market Cap
$150.91 million
Optionable
Optionable
Beta
1.10
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Raj Kannan (Age 60)
    CEO & Director
  • Dr. Jerry Wang
    Co-Founder & Chief Scientific Officer
  • Mr. Skelton Joseph
    Chief Financial Officer
  • Mr. Tianyi Zhang
    Vice President of Investor Relations
  • Mr. Cheng Li (Age 40)
    Chief Legal Officer
  • Ms. Gigi Qi Feng (Age 43)
    Chief Communications Officer
  • Dr. Weiming Tang Ph.D. (Age 58)
    Executive VP of Global Business Development & Chief Business Officer
  • Dr. Fernando J. Salle´s Ph.D.
    Senior VP and Head of U.S. & EU Business Development
  • Claire Xu
    Head of US site
  • Dr. John Hayslip M.D. (Age 47)
    Chief Medical Officer

IMAB Stock Analysis - Frequently Asked Questions

Should I buy or sell I-Mab stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for I-Mab in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMAB shares.
View IMAB analyst ratings
or view top-rated stocks.

What is I-Mab's stock price target for 2024?

4 Wall Street analysts have issued 12-month price targets for I-Mab's stock. Their IMAB share price targets range from $6.00 to $25.00. On average, they expect the company's share price to reach $12.25 in the next twelve months. This suggests a possible upside of 551.6% from the stock's current price.
View analysts price targets for IMAB
or view top-rated stocks among Wall Street analysts.

How have IMAB shares performed in 2024?

I-Mab's stock was trading at $1.90 on January 1st, 2024. Since then, IMAB stock has decreased by 1.1% and is now trading at $1.88.
View the best growth stocks for 2024 here
.

When is I-Mab's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our IMAB earnings forecast
.

What other stocks do shareholders of I-Mab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other I-Mab investors own include Inovio Pharmaceuticals (INO), Moderna (MRNA), ServiceNow (NOW), Novavax (NVAX), Gilead Sciences (GILD), Cisco Systems (CSCO), Enterprise Products Partners (EPD), G1 Therapeutics (GTHX), Intel (INTC) and Johnson & Johnson (JNJ).

When did I-Mab IPO?

I-Mab (IMAB) raised $100 million in an initial public offering on Thursday, January 16th 2020. The company issued 7,400,000 shares at $12.00-$15.00 per share. Jefferies and CICC served as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers.

Who are I-Mab's major shareholders?

I-Mab's stock is owned by a number of institutional and retail investors. Top institutional shareholders include GSA Capital Partners LLP (0.65%), Schroder Investment Management Group (0.38%), Barclays PLC (0.21%), abrdn plc (0.20%), Goldman Sachs Group Inc. (0.18%) and Goldman Sachs Group Inc. (0.18%).

How do I buy shares of I-Mab?

Shares of IMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMAB) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners